Single Fraction Stereotactic Body Radiation Therapy for Breast Cancer
This trial offers a new, single-fraction radiation treatment for patients with early stage breast cancer.
- Breast Cancer
3 Primary · 2 Secondary · Reporting Duration: 0-2 years
Awards & Highlights
3 Treatment Groups
5 Fraction Breast Stereotactic Body Radiation Therapy
1 of 3
1-3 Fraction Breast Stereotactic Body Radiation Therapy
1 of 3
Single Fraction Breast Stereotactic Body Radiation Therapy
1 of 3
40 Total Participants · 3 Treatment Groups
Primary Treatment: Single Fraction Stereotactic Body Radiation Therapy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18 - 99 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Liu, Yilan, Christopher Veale, Diana Hablitz, Helen Krontiras, Allison Dalton, Korie Meyers, Michael Dobelbower, et al.. 2022. “Feasibility and Short-term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation Therapy Regimen in Early-stage Breast Cancer Patients Receiving Partial Breast Irradiation”. Frontiers in Oncology. Frontiers Media SA. doi:10.3389/fonc.2022.901312.
- Drexell Hunter Boggs 2019. "RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03643861.
Frequently Asked Questions
How many participants can be accepted into this research endeavor?
"Affirmative, the data on clinicaltrials.gov indicates this trial is actively searching for participants and was posted on August 20th 2019 with a last update of November 7th 2022. The study requires 40 individuals who will be recruited from 1 medical institution." - Anonymous Online Contributor
Do I meet the requirements to partake in this research?
"This research is recruiting 40 individuals affected by [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) who are aged 18-99. Participants must meet the following criteria: biopsy confirmed invasive mammary carcinoma, ductal carcinoma in situ (DCIS) of the breast; medullary, papillary, mucinous (colloid), and tubular histologies allowed; over 50 years old; maximal pathologic tumor size less than 2.0 cm for invasive tumours or less than 2.5 cm for pure DCIS cases; estrogen receptor positivity (>10%); be eligible for conservative therapy with lumpectomy exhibiting a minimum margin width of two millimetres; clinically" - Anonymous Online Contributor
Is the age prerequisite for this clinical trial restricted to those over 20 years old?
"In order to participate in this clinical study, individuals must be aged 18-99. There are also 74 trials for minors and 2507 studies targeting those over the age of 65." - Anonymous Online Contributor
Is the enrollment period for this research still in progress?
"As indicated on clinicaltrials.gov, this trial is in the process of recruiting participants and was first posted on August 20th 2019 with its most recent revision made on November 7th 2022." - Anonymous Online Contributor